NASDAQ: EOCNEocene Ltd Stock
$3.41-0.08 (-2.29%)
Updated Oct 1, 2026
EOCN Price
$3.41
Fair Value Price
N/A
Market Cap
$3.41M
52 Week Low
$3.12
52 Week High
$13.20
P/E
-0.23x
P/B
0.27x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$11.34M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.44
Operating Cash Flow
-$9M
Beta
0.94
Next Earnings
Nov 25, 2026
Ex-Dividend
N/A
Next Dividend
N/A
EOCN Overview
Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EOCN's potential to beat the market
- EOCN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
EOCN
RankedUnranked of 464
RankedUnranked of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.84 | A | |
| $8.21 | A | |
| $39.57 | A |
Be the first to know about important EOCN news, forecast changes, insider trades & much more!
EOCN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EOCN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EOCN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EOCN is good value based on its book value relative to its share price (0.27x), compared to the US Biotechnology industry average (5.13x)
P/B vs Industry Valuation
EOCN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EOCN due diligence checks available for Premium users.
Valuation
EOCN fair value
Fair Value of EOCN stock based on Discounted Cash Flow (DCF)
Price
$3.41
Fair Value
$7.39
Undervalued by
53.88%
EOCN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EOCN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.23x
Industry
8.71x
Market
48.27x
EOCN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.27x
Industry
5.13x
EOCN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EOCN's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.7M
Profit Margin
0%
EOCN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$18.3M
Liabilities
$5.5M
Debt to equity
0.44
EOCN's short-term assets ($11.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EOCN's short-term assets ($11.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EOCN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
EOCN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.1M
Investing
$2.2M
Financing
$1.2M
EOCN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EOCN vs Biotech Stocks
Eocene Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.